Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5552W HIGH $1.69
Volume
5.44 K
Value Traded
20.38 K
Short % Float
5.01%
-19.68%Week
-29.47%1 Month
-25.07%3 Month
-39.11%6 Month
-98.91%5 Year
-99.69%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.18 M
EPS (TTM)
-0.98
P/E Ratio
-
Ent. Value
-34.21 M
Total Shares
12.59 M
Float Shares
11.46 M
Insiders
8.98%
Institutions
39.02%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
APRE Catalyst Timeline
Dated clinical, regulatory and corporate events for Aprea Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aprea Therapeutics, Inc.
379Total events
19Upcoming
63Tier-1 (high impact)
2018 to 2047Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Aprea to present at H.C. Wainwright 28th Annual Global Investment Conference
▲Patent GrantedIP / Competition
Expansion of intellectual property portfolio for WEE1 and ATR inhibitor programs
▲Patent GrantedAPR-1051IP / Competition
WEE1 inhibitor program patent portfolio includes granted non-U.S. patents
advanced/metastatic solid tumorssource ↗
▲Patent GrantedATRN-119DiscontinuedIP / Competition
ATR inhibitor program patent estate includes granted U.S. and non-U.S. patents
solid tumorssource ↗
▲Poster PresentationAPR-1051Presentation
Updated Phase 1 data presented at ASCO 2026
advanced solid tumorssource ↗
●Enrollment UpdateAPR-1051Trial
Dose escalation ongoing; enrollment in 300 mg cohort underway
advanced solid tumorssource ↗
▲Primary Endpoint MetAPR-1051Clinical Data
Confirmed partial response in one patient; unconfirmed PR in second patient
uterine carcinosarcoma with PPP2R1A mutationsource ↗
◆AbstractAPR-1051Presentation
Abstract accepted for ASCO 2026 on early results from ACESOT-1051 trial
advanced solid tumorssource ↗
◆Timing GuidanceAPR-1051Presentation
Further update from ACESOT-1051 trial expected in Q2 2026
advanced solid tumorssource ↗
◆Dose Finding UpdateAPR-1051Trial
Dose escalation to Dose Level 9 (300 mg once daily) planned
advanced solid tumorssource ↗
◆Enrollment UpdateAPR-1051Trial
Enrollment of additional patients with specific tumor types/mutations planned
advanced solid tumorssource ↗
▲Enrollment MilestoneAPR-1051Trial
Expanding enrollment to include at least 50 USC patients and PROC patients
uterine serous carcinoma, platinum-resistant ovarian cancersource ↗
▲Primary Endpoint MetAPR-1051Clinical Data
Confirmed partial response at 220 mg dose in PPP2R1A-mutated endometrial cancer
PPP2R1A-mutated endometrial cancersource ↗
▲Topline ReadoutAPR-1051Clinical Data
Two patients achieved unconfirmed partial responses at first scan in ACESOT-1051 trial
solid tumorssource ↗
◆Oral PresentationPresentation
Corporate update at Oppenheimer 36th Annual Healthcare Life Sciences Conference
▲Topline ReadoutAPR-1051Clinical Data
Second unconfirmed partial response reported in ACESOT-1051 trial
advanced solid tumorssource ↗
▲Preclinical PoCAPR-1051Preclinical
Early clinical proof-of-concept for APR-1051 in Phase 1 dose-escalation study
advanced solid tumorssource ↗
▲Primary Endpoint MetAPR-1051Clinical Data
Early clinical proof-of-concept demonstrated in Phase 1 dose-escalation study of APR-1051
advanced solid tumorssource ↗
▼Equity OfferingCorporate
Aprea announces $5.6 million private placement priced at-the-market under Nasdaq rules
▲Topline ReadoutAPR-1051Clinical Data
First unconfirmed partial response observed in ACESOT-1051 dose-escalation trial
advanced solid tumorssource ↗
◆Enrollment UpdateAPR-1051Trial
Enrollment in 220 mg dose level cohort currently underway
advanced solid tumorssource ↗
◆Topline ReadoutAPR-1051Clinical Data
Availability of further safety and efficacy data from ACESOT-1051
solid tumorssource ↗
▼Trial DiscontinuedATRN-119DiscontinuedTrial
ABOYA-119 study closed to focus resources on APR-1051
solid tumorssource ↗
◆Enrollment UpdateAPR-1051Trial
Enrolling patients in 220 mg cohort (Cohort 8) of ACESOT-1051
solid tumorssource ↗
◆Protocol AmendmentAPR-1051Trial
Amended protocol to augment HPV-positive patients after encouraging activity at 70 mg
HPV-positive head and neck cancersource ↗
▼Enrollment PausedATRN-119DiscontinuedTrial
Pausing further enrollment in once-daily and twice-daily monotherapy arms of ABOYA-119
solid tumorssource ↗
▼Equity OfferingCorporate
Aprea announces $3.1 million private placement priced at-the-market under Nasdaq rules
◆Dose Finding UpdateAPR-1051Trial
Advanced into 150 mg once daily cohort in ACESOT-1051 trial
solid tumorssource ↗
▲Dose Finding UpdateATRN-119DiscontinuedTrial
Recommended Phase 2 dose identified for QD dosing in ABOYA-119 trial
solid tumorssource ↗
◆Poster PresentationAPR-1051Presentation
Poster presentation of early safety and efficacy data for APR-1051 at AACR-NCI-EORTC conference
advanced solid tumorssource ↗
◆Topline ReadoutAPR-1051Clinical Data
Clinical update from ACESOT-1051 trial showing early signals of activity
advanced solid tumorssource ↗
◆Poster PresentationATRN-119DiscontinuedPresentation
Poster presentation of updated data from ABOYA-119 phase 1/2a trial of ATRN-119
advanced solid tumors harboring DNA damagesource ↗
◆Oral PresentationATRN-119DiscontinuedPresentation
Poster presentation of updated ABOYA-119 data at AACR-NCI-EORTC conference
advanced solid tumorssource ↗
▲Preclinical PoCAPR-1051Preclinical
APR-1051 shows single agent activity in HPV+ HNSCC preclinical studies
HPV+ head and neck squamous cell carcinomasource ↗
▲Dose Finding UpdateATRN-119DiscontinuedTrial
RP2D determined for ATRN-119 monotherapy at 1,100 mg once daily
advanced solid tumorssource ↗
▼Enrollment PausedATRN-119DiscontinuedTrial
Pausing further enrollment in monotherapy dosing arms of ABOYA-119
advanced solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How APRE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-01 | APR-1051 (WEE1 kinase inhibitor) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C40 / 100
Pipeline Score
$132M
Pipeline Value
Undervalued
Valuation Signal
3
Drugs Scored
15.0x
rNPV / MCap
Top 38%
Micro Cap(rank 251 of 658)
Percentile Rank
Aprea Therapeutics, Inc. carries a moderate pipeline score (40/100), with $570M risk-adjusted pipeline value, led by APR-246 in Hematologic Neoplasms (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| APR-246 Small moleculeCompletedNCT03745716 | MDS | Phase 3 | COMPLETED | 154 | Jan 14, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every APRE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| APR-1051 | uterine serous carcinoma (USC) and Cyclin E-overexpressing platinum-resistant ovarian cancer (PROC) | Phase 1 | 2026-08-12 | early single-agent activity for APR-1051, including partial responses and disease stabilizationRead More | Aprea Therapeutics Announces Second Quarter 2026 Financial ResultsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hamill John P.Officer (SrVP/CFO/Prin Fin & Acct Ofcr) | Buy | 30,978 30,978 held | $0.00 | 03/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in APRE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| DAFNA Capital Management LLC | 0 % (-100 %) | 202.00 K | 137.17 K |
APRE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How APRE ranks across every disease it competes in
Competitive Position is a premium feature
See how APRE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAPRE News
APREAprea Therapeutics to Present at October Conferences
Aprea Therapeutics will present at the 2026 Maxim Growth Summit and the Regional Biotechnology Conference. CEO Oren Gilad will participate in discussions aimed at showcasing the company's targeted therapies for biomarker-defined cancers. The events will take place in New York City and Doylestown, PA, respectively.
Read more →APREAprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
Aprea Therapeutics announced that updated interim results from its Phase 1 ACESOT-1051 study of the WEE1 inhibitor APR-1051 will be presented at the 38th EORTC-NCI-AACR Symposium. The presentation is scheduled for November 18-20, 2026, in Barcelona, Spain. The company aims to share its findings with leading oncology professionals to foster advancements in cancer treatment.
Read more →APREAprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Aprea Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. CEO Oren Gilad will discuss the company's targeted therapies for biomarker-defined cancers. Aprea is known for its innovative approach to minimize toxicity while effectively treating various cancer types.
Read more →APREAprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Aprea Therapeutics has announced an expansion of its intellectual property portfolio, which is crucial for its precision oncology programs. The company is focusing on its WEE1 kinase inhibitor and ATR inhibitor programs, with ongoing clinical trials for both. This expansion reflects Aprea's commitment to innovation and its strategy to protect the long-term value of its oncology therapies.
Read more →APREAprea Therapeutics Announces Second Quarter 2026 Financial Results
Aprea Therapeutics reported positive developments in its Phase 1 ACESOT-1051 trial for APR-1051, an oral WEE1 inhibitor. The company is expanding enrollment and advancing dose escalation, with early data showing clinical activity. Financial results indicate a cash position of $41.2 million, though operating losses have increased. Aprea plans to evaluate APR-1051 in multiple cancer types and report further data in Q4 2026.
Read more →APREAprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
Aprea Therapeutics has provided an update on its Phase 1 ACESOT-1051 trial for the WEE1 inhibitor APR-1051, indicating accelerated enrollment and plans for combination therapies. The next clinical data update is expected in Q4 2026, with an expansion of clinical sites from three to ten. The company aims to broaden its development strategy, targeting specific cancer types with significant unmet needs.
Read more →APRE▼ -8.6%on this news
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
Aprea Therapeutics presented updated Phase 1 data for its WEE1 inhibitor APR-1051 at ASCO 2026, highlighting early clinical activity with partial responses and stable disease in patients with advanced solid tumors. The study demonstrated manageable tolerability, with adverse events primarily being mild. Enrollment is expanding into uterine serous carcinoma and platinum-resistant ovarian cancer, with completion of dose escalation expected by Q2 2027.
Read more →APREAprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Aprea Therapeutics reported its Q1 2026 financial results, highlighting progress in the ACESOT-1051 trial of APR-1051, a WEE1 inhibitor. The trial has shown two partial responses and good tolerability among patients. The company closed a $30 million private placement to support further development and expansion of patient enrollment. Additional data will be presented at the ASCO 2026 Annual Meeting.
Read more →APRE▼ -7.5%on this news
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
Aprea Therapeutics announced that an abstract regarding early results from its Phase 1 trial of the WEE1 inhibitor APR-1051 has been accepted for presentation at the 2026 ASCO Annual Meeting. This trial, referred to as ACESOT-1051, focuses on patients with advanced solid tumors. The presentation is scheduled for May 30, 2026, with the session highlighting developmental therapeutics and molecularly targeted agents. Aprea is known for its targeted therapies, striving to improve cancer treatment outcomes while minimizing effects on healthy cells.
Read more →APRE▼ -7.7%on this news
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
Aprea Therapeutics has announced the successful closing of an oversubscribed $30 million private placement financing. The company plans to utilize these funds to support the ongoing development of APR-1051, specifically focusing on selected patient populations for whom the WEE1 mechanism is advantageous. The financing reflects strong interest from prominent investors and aims to enhance clinical studies, particularly targeting uterine serous carcinoma and platinum-resistant ovarian cancer. This funding is expected to notably progress Aprea's research efforts in targeted therapies.
Read more →APRE▲ +8.2%on this newsshared move
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
Aprea Therapeutics announced an oversubscribed private placement financing expected to yield approximately $30 million. The financing was led by Soleus Capital and includes participation from other investors. The funds will be utilized for general corporate purposes and research and development, particularly in ongoing clinical trials for targeted therapies in oncology. The offering is anticipated to close by March 31, 2026.
Read more →APRE▲ +8.2%on this newsshared move
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
Aprea Therapeutics has reported a confirmed partial response in a patient with PPP2R1A-mutated endometrial cancer during the ongoing Phase 1 ACESOT-1051 trial of APR-1051. The trial aims to evaluate the safety and preliminary anti-tumor activity of this WEE1 kinase inhibitor. Early data suggests promising anti-tumor activity without significant toxicity, with further updates expected in 2026.
Read more →APREAprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Aprea Therapeutics has reported its fourth-quarter and full-year financial results for 2025, demonstrating a focus on advancing targeted cancer therapies. Notably, the ongoing ACESOT-1051 trial of APR-1051 showed early proof-of-concept, with two patients achieving partial responses. Despite the progress, the company continues to face significant financial losses and uncertainties regarding future clinical trial outcomes. Aprea's financial situation has improved with recent private placements, which provide better flexibility for upcoming challenges.
Read more →APRE▲ +21.3%on this news· ran to +36% by day 1
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
Aprea Therapeutics announced promising preliminary results from its Phase 1 ACESOT-1051 trial of the WEE1 inhibitor APR-1051, reporting a second unconfirmed partial response in a patient with advanced endometrial cancer. The patient showed a 50% reduction in target lesions and a significant drop in CA-125 levels. The trial continues to enroll patients, focusing on those with specific genetic mutations.
Read more →APREAprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Aprea Therapeutics will present a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. The presentation will be led by Dr. Oren Gilad, the company's President and CEO. Aprea focuses on developing therapies that target cancer-specific vulnerabilities while minimizing harm to healthy cells.
Read more →APREAprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
Aprea Therapeutics has expanded its global patent portfolio with new patents granted in Australia and Japan, ensuring exclusivity for its WEE1 and ATR programs until 2045. The lead candidate, APR-1051, is currently in Phase 1 trials, demonstrating early clinical promise. This strategic move positions Aprea for long-term growth and value creation in the oncology space.
Read more →APRE▼ -6.8%on this news
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
Aprea Therapeutics has appointed Dr. Eugene Kennedy as Chief Medical Advisor following promising early clinical results for its WEE1 inhibitor, APR-1051. Dr. Kennedy brings over 20 years of experience in oncology drug development, which Aprea believes will enhance its clinical leadership. The company aims to optimize dose and patient selection in its ongoing clinical trials.
Read more →APRE▼ -22.8%on this news
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
Aprea Therapeutics announced early clinical proof-of-concept for its WEE1 inhibitor APR-1051 in the ongoing Phase 1 ACESOT-1051 trial. A patient with PPP2R1A-mutated uterine serous carcinoma exhibited a 50% reduction in tumor size and a significant decrease in CA-125 levels. The trial continues to evaluate higher dose cohorts, indicating potential for broader therapeutic applications.
Read more →APRE▼ -22.8%on this newsshared move
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Aprea Therapeutics announced a $5.6 million private placement to support its clinical studies. The offering includes 6,288,857 shares of common stock and warrants, priced at $0.89 each. The funds will be used for general corporate purposes and research. The closing is expected around January 30, 2026, pending customary conditions.
Read more →About Aprea Therapeutics, Inc.
Headquarters3805 OLD EASTON ROAD, DOYLESTOWN, PA, 18902
Founded2002
BIOPHARMAWATCH ELITE PLUS
Trade the next APRE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime